XXXX promoter hypermethylation as a predictor of decreased risk of recurrence following radical prostatectomy.

@entity1 @entity59884 @entity21251 @entity23883 @entity263 @entity5 @entity5962 @entity19572 @entity3 @entity33767 @entity204
PURPOSE: To evaluate the prognostic significance of six epigenetic biomarkers ( @entity33767 , @entity5962 , @entity19572 , @entity59884 , @entity21251 , and @entity23883 promoter hypermethlation) in a homogeneous group of @entity263 @entity1 , following radical prostatectomy (RP). @entity1 AND METHODS: Biomarker analyses were performed retrospectively on @entity5 from 95 @entity263 @entity1 all with a Gleason score of 3   +   4   =   7 and a minimum follow-up period of 8 years. Using Quantitative Methylation Specific PCR (QMSP), we analyzed the promoter region of six genes in primary @entity263 tissues. Time to any progression was the primary endpoint and development of @entity263 was a secondary endpoint. The association of clinicopathological and biomolecular risk factors to recurrence was performed using the Log-rank test and Cox proportional hazards model for multivariate analysis. To identify independent prognostic factors, a stepwise selection method was used. RESULTS: At a median follow-up time of 10 years, 48 @entity1 (50.5%) had evidence of recurrence: Biochemical/PSA relapse, @entity3 , or @entity204 from @entity263 . In the final multivariate analysis for time to progression, the significant factors were: Older age, HR   =   0.95 (95% CI: 0.91, 1.0) (P   =   0.03), positive lymph nodes HR   =   2.11 (95% CI: 1.05, 4.26) (P   =   0.04), and decreased hypermethylation of @entity33767 HR   =   0.45 (95% CI: 0.2, 1.0) (P   =   0.05). CONCLUSIONS: Methylation status of @entity33767 in the @entity263 specimen may predict for time to recurrence in Gleason 3   +   4   =   7 @entity1 undergoing prostatectomy. These results should be validated in a larger and unselected cohort.
